Celator Pharmaceuticals Inc. (CPXX) announced after the bell Monday that its Phase 3 trial of VYXEOS Liposome for Injection met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with high-risk acute myeloid leukemia.
from RTT - Hot Stocks http://ift.tt/251X7jM
via IFTTT
No comments:
Post a Comment